Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.86 USD
-0.06 (-1.53%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 321 - 340 ( 403 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
FDA Approval of Exservan- Oral Film for Treatment of ALS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Financials: Revenue Guidance Raised for 2019 - Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
2019 Top-Line Guidance Reaffirmed; Diazepam Film Filing Completion Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Preview; Pipeline Progress - Positive Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
AQST-108 Phase 1 Completion; FDA Discussion Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
108/Anaphylaxis: Promising Phase 1 Proof-of-Concept Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L